Science bounties

Reanalyze public mouse cecal-metabolite measurements to identify whether early-life-stress-associated differences recur in descendants once cage, litter, experimental batch and multiple comparisons are considered. Deliver reproducible effect estimates and a defensible list of candidates for mechanistic follow-up—or a supported conclusion that none can yet be prioritized.

Build a reproducible target-prioritization sensitivity benchmark from NASA OSD-48's deposited mouse liver differential-expression results. Determine which flight-associated signals are consistent across tissue-handling strata and two published processing outputs, and which should be held for validation before entering a space-resilience target list.

Benchmark the fidelity of three culture conditions to a public freshly isolated mouse tumour-cell reference. Quantify how the culture ranking changes with distance definition and reference-sample uncertainty, then recommend which comparison merits experimental validation for a synthetic tumour-microenvironment program.

Reanalyze public orexin-receptor dose-response data to determine what a cAMP assay can and cannot establish about functional agonism. Produce a reproducible comparison with Gq/IP signaling that helps the OX2R-004 project choose an interpretable functional readout before committing to its proposed assay panel.

Quantify the safety precision of two public RTB101 trials and produce explicit evidence constraints for advancing a clinically tested immunometabolism candidate. Determine which prespecified excess-risk margins are excluded by aggregate data and which remain unresolved. “No clear difference” must not be treated as demonstrated safety or longevity benefit.

Build a reproducible event and recruitment calculator to help Steam Collective decide whether a future community-sauna cohort could meaningfully evaluate all-cause mortality associations. Ground the comparison in the published Finnish cohort, then show how weaker associations, exposure imbalance and lower event rates change feasibility. This is a research-planning purchase, not a claim that sauna prevents death.

Build a reproducible recruitment feasibility analysis for evaluating methotrexate outcomes in genetic subgroups. Use the published genotype counts from a Mexican rheumatoid arthritis cohort to show how total cohort size affects the chance of obtaining adequately represented subgroups. The useful result is a defensible planning calculator and a clear account of what remains unknown before a calibrated prediction model could be evaluated.

Reanalyze the public processed human expression matrix from GSE107063 to identify reproducible signals associated with soft gel, intermediate gel and glass culture. Deliver a benchmark that helps a synthetic tumour-microenvironment project decide which transcript-level changes warrant validation when selecting culture stiffness. A complete result showing instability or insufficient evidence is eligible; novel biomarkers are not required.

Build a reproducible covariance-sensitivity and recruitment calculator using the public aggregate blood-pressure data from a randomized crossover UVA experiment. Determine what its published means can establish, what depends on unknown within-person covariance, and which covariance measurements a future pilot should collect. This supports the Sun-Human Interface project's hypothesis-driven UVA/nitric-oxide research; it is not an exposure recommendation.

Deliver a decision-ready validation design for a STAT6 small-molecule screen: separate evidence of direct binding, cellular pathway modulation and disease-relevant activity, and specify how ambiguous or contradictory results affect advancement. Ground the design in two fixed public studies of AS1517499. This is a remote experimental-design deliverable; no experiment, novel binder or proprietary prediction is required or claimed.

Build a reproducible missing-outcome sensitivity analysis for the 2014 randomized trial of Lactobacillus reuteri DSM 17938 in infant colic. Deliver a decision brief identifying which treatment and subgroup claims the aggregate evidence can support, and which diary-retention uncertainties should shape a future objectively measured trial. A negative or inconclusive conclusion is eligible.

Produce a reproducible aggregate-data audit of cross-population evidence for BCL11A as a sickle-cell research target. Determine which conclusions about direction, magnitude and transferability are supported by the fixed studies below, and which remain unresolved. A well-supported negative or inconclusive conclusion is eligible.